相关实验视频
Updated: Jun 18, 2025

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
Published on: October 10, 2011
由KCTD17介导的Ras稳定促进肝细胞癌的进展
Young Hoon Jung1,2,3, Yun Ji Lee1,2,3, Tam Dao4
1Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Korea.
含有17 (KCTD17) 蛋白质的通道四聚化域通过稳定Ras.促进肝细胞癌 (HCC). 用反感性寡核酸抑制KCTD17减少了小鼠的瘤生长,这表明KCTD17是潜在的HCC治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 含有17 (KCTD17) 的通道四重化域是cullin3 (Cul3) 泛酸酶复合物的适配器.
- 对于KCTD17在肝细胞癌 (HCC) 发病过程中的作用尚不清楚.
- 这项研究研究了KCTD17的临床特征和对HCC进展的机制影响.
研究的目的:
- 阐明KCTD17在HCC中的临床特征.
- 研究KCTD17影响HCC进展的分子机制.
- 评估KCTD17导向的HCC治疗方法.
主要方法:
- 分析来自HCC患者的转录组数据.
- 评估肝细胞特异性KCTD17缺陷小鼠中HCC进展的评估,这些小鼠接受了二甲基尼托胺 (DEN) 治疗.
- 在KCTD17导向的反感性寡核酸 (ASO) 在HCC.小鼠模型中的体内测试.
主要成果:
- 在HCC瘤和小鼠模型中,KCTD17的表达被上调.
- KCTD17针对氨酸拉链状转录调节器1 (Lztr1) 进行降解,稳定Ras并促进肝癌细胞的增殖,迁移和伤口愈合.
- KCTD17 缺乏或 ASO 治疗减少了 HCC 致癌,瘤生长和 Ras 蛋白水平.
结论:
- KCTD17稳定了Ras和下游的信号通路,推动了HCC的进展.
- KCTD17代表了肝细胞癌的潜在新型治疗点.
- 用ASO准KCTD17在临床前HCC模型中显示出治疗潜力.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
相关概念视频
The Ras Gene
Ras is a...
MAPK Signaling Cascades
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity: